Orshe

One of every five kids and 9 of 10 older Americans took at least one prescription drug in the previous month, says a survey taken in 2008.

Excerpt from: Almost Half of Americans Took a Prescription Drug in Past Month

Also: NEJM editors say Meridia should be yanked; stem cell plaintiffs explain themselves to the WSJ; are hospital profits the driver of health-care costs?

See the rest here: A.M. Vitals: Allergan Will Settle Off-Label Botox Allegations

About 60 million Americans have medical conditions that should be known in an emergency, but only a fraction wear medical ID or carry their health information.

See the rest here: Boosting the Use of Medical Alert Bling To Save Lives

Also: Most C-sections performed before labor starts; American companies push into Chinese electronic medical record market; investigators looking at health-care credit cards.

Read more:  A.M. Vitals: Genzyme Points to MS Drug As Sign Sanofi Bid is Too Low

eMarketer estimates online spending by U.S. health-care and pharma companies will hit $1.52 billion in 2014.

Excerpt from:  Report: Pharma Digital Spending Growing — But Slowly

Also: experimental melanoma drug results; California insurance news; radiation at Walter Reed.

Here is the original post:  A.M. Vitals: Judge Won’t Nix Generic Version of Sanofi’s Lovenox

Some 20% of respondents to the Consumer Reports survey say they’ve asked their doctor for a drug they saw advertised.

Here is the original: More Than a Quarter of Prescription Takers Cut Corners to Save Money

Also: Hepatitis E vaccine study; new self-referral rule for medical imaging; NAIC and HHS on medical-loss ratio.

Original post:  A.M. Vitals: Federal Medical Privacy Rules Go Back for Do-Over

The vote was 20-2 against recommending the drug’s approval for use against fibromyalgia.

Here is the original:  FBI Agent, 19 Others Vote Against Jazz Pharma’s Drug For Fibromyalgia

Also: Low demand so far for high-risk pools; egg recall; “junk” DNA linked to disease.

Here is the original: A.M. Vitals: FDA Advisory Panel Approves Wider Use of Lilly’s Cymbalta